Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Backers of WTO vaccine waiver ask opponents to join talks - document

Published 05/17/2021, 11:52 AM
Updated 05/17/2021, 12:48 PM
© Reuters. FILE PHOTO: A logo is pictured on the headquarters of the World Trade Organization (WTO) in Geneva, Switzerland, June 2, 2020. REUTERS/Denis Balibouse

By Emma Farge

GENEVA (Reuters) -Supporters of a proposal to waive patent rights on COVID-19 vaccines at the World Trade Organization are set to call on opponents to join the negotiations, stressing the gravity of the pandemic, a draft document showed on Monday.

Talks at the WTO on temporarily waiving IP rights have been deadlocked for months. But U.S. President Joe Biden's decision earlier this month to back talks for a waiver has raised hopes that the few remaining wealthy-country opponents could also switch camps.

The EU has since backed a U.S. proposal to discuss waiving patent protections, although Switzerland said it left many questions unanswered.

"The cosponsors call on all delegations who have not yet indicated that they will join text-based discussions, to do so as soon as possible," the 62 proponents of the waiver, including India and South Africa that initially floated the proposal, said in a co-authored draft statement.

"Continuous mutations and emergence of new variants of SARS-COV-2 highlight the significant uncertainties and complexities of controlling SARS-COV-2 and underscore the urgency of this proposal," they said.

"A failure to respond in a timely manner on the waiver proposal undermines the legitimacy and credibility of the WTO."

That call was echoed by the WTO's chief on Monday.

"We need to sit down at the negotiating table and actually look at a text. People are dying, and the faster we can sit down and look at a text the better," said Ngozi Okonjo-Iweala at a virtual meeting of the Paris Peace Forum.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

India's and South Africa's original waiver proposal last October argued that IP rules are hindering the scale-up of COVID-19 vaccine production.

Critics, including large pharmaceuticals industry groups as well as Pfizer (NYSE:PFE) that makes a COVID-19 vaccine, say an IP waiver will not immediately increase vaccine production and that the current supply issues are more complex.

Pfizer has said any waiver could disrupt the flow of raw materials.

The statement from proponents seen by Reuters said that a new proposal would be issued soon to clarify its scope and the time period of its application.

However, experts have warned that getting agreement at the WTO, which typically operates through consensus, could still take months even with U.S. backing.

The next formal TRIPS council meeting at the WTO is scheduled for June 8.

Latest comments

Too little too late and they know it. Just putting in the effort in an attempt to justify their worth.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.